183
Participants
Start Date
December 9, 2024
Primary Completion Date
June 30, 2027
Study Completion Date
December 29, 2028
ARX517
ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.
Apalutamide
Oral tablet and will be given once daily by mouth.
Abiraterone acetate
Oral tablet and will be given once daily by mouth.
Prednisone
Oral tablet and will be given once daily in metastatic castration-sensitive prostate cancer( mCSPC) and twice daily in metastatic castration-resistant prostate cancer (mCRPC) cohort by mouth.
RECRUITING
Carolina Urologic Research Center, Myrtle Beach
RECRUITING
Winship Cancer Institute of Emory University, Atlanta
RECRUITING
University Hospitals Cleveland Medical Center, Cleveland
RECRUITING
Washington University St. Louis School Medicine Siteman Cancer Center, St Louis
COMPLETED
GU Research Network, Omaha
RECRUITING
UC San Diego Moores Cancer Center, La Jolla
RECRUITING
University of Washington, Seattle
RECRUITING
University of California, Los Angeles School of Medicine, Los Angeles
RECRUITING
UCSF Medical Center at Mission Bay, San Francisco
RECRUITING
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
RECRUITING
University of Michigan Comprehensive Cancer Center, Ann Arbor
RECRUITING
Weill Cornell Medical College, New York
Janssen Research & Development, LLC
INDUSTRY